Skip to content

Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology

Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04886908
Enrollment
373
Registered
2021-05-14
Start date
2021-02-09
Completion date
2021-07-28
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer

Brief summary

Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity. The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.

Interventions

Data extraction from medical files

Sponsors

Brugmann University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients.

Exclusion criteria

Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.

Design outcomes

Primary

MeasureTime frameDescription
Age5 minutesAge of the patient at the time of diagnose
Sex5 minutesSex of the patient
Name of the department in which the patient is followed5 minutesOphthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital
Tumor anatomical location5 minutesEyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone.
Tumor size5 minutesTumor size in millimeters
Laterality5 minutesLaterality: left, right, median
Multiple or single tumor5 minutesMultiple or single tumor
Primitive tumor or recidive5 minutesPrimitive tumor or recidive
Risk factor: phototype5 minutesPhototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns.
Risk factor: immunosuppression (yes/no)5 minutesPathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma
Risk factor: keratosis5 minutesActinic keratosis of the face
Risk factor: solar exposition (yes/no)5 minutesLived in a sunny European country\> 1 year, lived in a sunny country outside Europe\> 1 year, sunbed use\> 1 session, history of solar erythema during childhood.
Diagnosis5 minutesTime between the appearance of the tumor and the first consultation
Locoregional extension report (yes/no)5 minutesLocoregional extension report (yes/no)
Histological diagnosis of the tumor5 minutesHistological diagnosis of the tumor
Healthy or invaded margins5 minutesHealthy or invaded margins
Superficial or infiltrating tumor5 minutesSuperficial or infiltrating tumor
Diagnostic method5 minutesDiagnostic method: curettage, punch, biopsy, flattening
Surgical management method5 minutesBiopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026